Related Experiment Video
Updated: Jul 7, 2025
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
Exploring the hub genes and potential drugs involved in Fanconi anemia using microarray datasets and bioinformatics
Alaa R Hameed1, Sama Fakhri Ali2, Taghreed N Almanaa3
1Department of Medical Laboratory Techniques, School of Life Sciences, Dijlah University College, Baghdad, Iraq.
Abstract:
Fanconi anemia (FA) is a genetic disorder that occurs when certain genes responsible for repairing DNA replication and promoting homologous recombination fail to function properly. This leads to severe clinical symptoms and a wide range of cancer-related characteristics. Recent treatment approaches for FA involve hematopoietic stem cell transplantation (HSCT), which helps restore the population of stem cells. A survival study using p-values indicated that specific hub genes play a significant role in diagnosing and predicting the disease. To find potential medications that interact with the identified hub genes, researchers inferred drugs. Among hub genes, TP53 was found to be particularly promising through computational analysis. Further investigation focused on two drugs, Topiramate and Tocofersolan predicted based on drug bank database analysis. Molecular docking strategies were employed to assess the best binding pose of these drugs with TP53. Topiramate showed a binding affinity of -6.5 kcal/mol, while Tocofersolan showed -8.5 kcal/mol against the active residues within the binding pocket. Molecular dynamics (MD) simulations were conducted to observe the stability of each drug's interaction with the TP53 protein over time. Both drugs exhibited stable confirmation with only slight changes in the loop region of the TP53 protein during the simulation intervals. Results also shows that there was a high fluctuation observed during apo-sate simulation time intervals as compared to complex system. Hence, it is suggested that the exploration of structure-based drug design holds promising results to specific target. This could potentially lead to a breakthrough in future experimental approaches for FA treatment.
Insights
Fanconi anemia (FA) treatment shows promise with TP53 gene targeting. Computational analysis identified Topiramate and Tocofersolan as potential drugs, with Tocofersolan showing stronger binding affinity for TP53.
Area of Science:
- Genetics and Molecular Biology
- Computational Chemistry
- Pharmacology
Background:
- Fanconi anemia (FA) is a genetic disorder characterized by DNA repair defects, leading to severe symptoms and cancer predisposition.
- Hematopoietic stem cell transplantation (HSCT) is a current treatment, but novel therapeutic strategies are needed.
- Identifying key genes and potential drug targets is crucial for advancing FA treatment.
Purpose of the Study:
- To identify significant hub genes in Fanconi anemia (FA) for disease diagnosis and prediction.
- To computationally screen for potential drugs that interact with identified FA-related hub genes, specifically TP53.
- To evaluate the binding affinity and stability of candidate drugs (Topiramate, Tocofersolan) with the TP53 protein.
Main Methods:
- Survival analysis to identify significant hub genes in FA.
- Drug bank database analysis and computational screening for drug-gene interactions.
- Molecular docking and molecular dynamics (MD) simulations to assess drug-protein binding and stability.
Main Results:
- TP53 was identified as a promising hub gene through computational analysis.
- Tocofersolan exhibited a higher binding affinity (-8.5 kcal/mol) to TP53 compared to Topiramate (-6.5 kcal/mol).
- Both drugs demonstrated stable interactions with TP53 during molecular dynamics simulations, suggesting therapeutic potential.
Conclusions:
- Structure-based drug design targeting specific genes like TP53 shows promise for Fanconi anemia (FA) treatment.
- Topiramate and Tocofersolan are identified as potential therapeutic agents for FA, warranting further experimental investigation.
- These findings could pave the way for new experimental approaches and breakthroughs in FA therapy.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
02:34DNA Microarrays